key: cord-0697316-hphb36km authors: Goffin, Eric; Candellier, Alexandre; Vart, Priya; Noordzij, Marlies; Arnol, Miha; Covic, Adrian; Lentini, Paolo; Malik, Shafi; Reichert, Louis J; Sever, Mehmet S; Watschinger, Bruno; Jager, Kitty J; Gansevoort, Ron T title: COVID-19 related mortality in kidney transplant and hemodialysis patients: a comparative, prospective registry based study date: 2021-06-16 journal: Nephrol Dial Transplant DOI: 10.1093/ndt/gfab200 sha: a5ae3590fbdb141602775e679094090971481f7c doc_id: 697316 cord_uid: hphb36km BACKGROUND: COVID-19 has exposed hemodialysis patients and kidney transplant recipients to an unprecedented life-threatening infectious disease raising concerns about kidney replacement therapy (KRT) strategy during the pandemic. The present study investigated the association of type of KRT with COVID-19 severity adjusting for differences in individual characteristics. METHODS: Data on kidney transplant recipients and hemodialysis patients diagnosed with COVID-19 between February 1(st) and December 1(st) 2020 were retrieved from ERACODA. Cox regression models adjusted for age, sex, frailty and comorbidities were used to estimate hazard ratios (HR) for 28-day mortality risk in all patients and in the subsets who were tested because of symptoms RESULTS: In total, 1,670 patients (496 functional kidney transplant and 1,174 hemodialysis) were included. 16.9% of kidney transplant and 23.9% of hemodialysis patients died within 28 days of presentation. The unadjusted 28-day mortality risk was 33% lower in kidney transplant recipients compared with hemodialysis patients (HR: 0.67, 95%CI: 0.52-0.85). In a fully adjusted model, the risk was 78% higher in kidney transplant recipients (HR: 1.78, 95%CI: 1.22-2.61) compared with hemodialysis patients. This association was similar in patients tested because of symptoms (fully adjusted model HR: 2.00, 95%CI: 1.31-3.06). This risk was dramatically increased during the first post-transplant year. Results were similar for other endpoints (e.g. hospitalization, ICU admission, mortality beyond 28 days) and across subgroups. CONCLUSIONS: Kidney transplant recipients had a greater risk of a more severe course of COVID-19 compared with hemodialysis patients; they therefore require specific infection mitigation strategies. Since the start of the pandemic in December 2019, the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has exposed patients treated with kidney replacement therapy (KRT) to an unprecedented life-threatening infectious disease: COVID-19. 1, 2 In-center hemodialysis are at higher risk for COVID-19 related mortality, independent from known risk factors such as obesity, ischemic heart disease and lung disease. 2 Kidney transplant recipients also represent a vulnerable population for viral diseases because of their immunosuppressive agents and are at specifically high risk for COVID-19 related mortality. 3 COVID-19 reported case fatality rates vary greatly per country owing to differences in public health policy, case ascertainment and testing capacity. 4, 5 In the European Renal Association COVID-19 registry, that included 4,298 kidney failure patients, 28-day mortality was 20.0% in 3,285 patients receiving dialysis and 19.9% in 1,013 recipients of a transplant. 6 The ERACODA database (1, 073 patients) reported a 28-day case fatality rate of 25.0% in 768 dialysis patients and 21.3% in 305 kidney transplant recipients during the first wave. 7 Other reports based on regional or national registries have also suggested lower mortality in kidney transplant than in hemodialysis patients. 8, 9 These data raise the question whether there is an effect of type of KRT in COVID-19 related outcomes. It should be noted that dialysis patients are in general older and have a higher prevalence of comorbid conditions than kidney transplant recipients. When analyzing the association of type of KRT with outcome, analyses should be adjusted for such differences in baseline characteristics. When comparing COVID-19 mortality rates in dialysis patients versus kidney transplant recipients, another complicating factor is the way how patients were diagnosed to have COVID-19. In hemodialysis units screening for COVID-19 may rely not only on symptoms but also as part of routine surveillance or screening after contact, whereas transplant patients are most often tested because they presented with symptoms. Given these considerations we aimed in the present study to determine whether hemodialysis or kidney transplantation are associated with mortality in kidney failure patients with COVID-19 while accounting for comorbidities and the reason for COVID-19 testing. For this study we used data from ERACODA. 10 This database was established in March 2020 and currently involves cooperation of approximately 200 physicians representing over 130 centers in 31 countries, mostly in Europe. Data was collected on adult (> 18 years) patients with kidney failure, either on hemodialysis or living with a functioning kidney allograft, who were diagnosed with COVID-19 based on a positive result on a real-time polymerase chain reaction assay of nasal and/or pharyngeal swab specimens, and/or compatible findings on CT scan or chest X-ray of the lungs. Data are voluntarily reported from outpatients and hospitalized patients by physicians responsible for the care of these patients. The ERACODA database is hosted at the University Medical Center Groningen, the Netherlands. Data is recorded using REDCap software (Research Electronic Data Capture, Vanderbilt University Medical Center, Nashville, TN, USA) for data collection. 11 Patient information is stored pseudonymized. The study was approved by the Institutional Review Board of the University Medical Center Groningen (Netherlands) who deemed the collection and analysis of data exempt from ethics review regarding the Medical Research Involving Human Subjects Act (WMO). Detailed information was collected on patient (age, sex, ethnicity, frailty, comorbidities, hospitalization and medication use) and COVID-19 related characteristics (reason for COVID-19 screening, symptoms, vital signs and laboratory test results) at presentation. Frailty was assessed using the Clinical Frailty Score developed by Rockwood et al. 12 This score is widely used in non-COVID-19 epidemiological studies and ranges from 1, representing very fit, to a score of 9, representing terminally ill. Comorbidities were recorded from patient charts and obesity was defined as a Body Mass Index >30 kg/m 2 . Kidney function was assessed by estimating glomerular filtration rate (eGFR) from serum creatinine at presentation using the CKD-EPI equation. Among dialysis patients, eGFR was assumed to be 7 0 for those with residual diuresis ≤200 ml/day, and 5 ml/min/1.73m 2 for those with residual diuresis >200 ml/day. The primary outcome was vital status at day 28 and the secondary outcomes were hospitalization, Intensive Care Unit (ICU) admission and in-hospital mortality within 28 days after presentation. Baseline characteristics are presented for the total population, for transplant recipients and dialysis patients separately, and by reason for COVID-19 testing i.e. the presence of symptoms versus contact with a COVID-19 positive person/routine screening of patients who may have been asymptomatic. Continuous data are presented as mean ± standard deviation (SD) or as median and interquartile range in case of a non-normal distribution of data. Categorical data are presented as percentages. Characteristics were compared between groups using student's t-test for continuous variables (Mann-Whitney U-test for nonnormally distributed data) and Pearson chi-2 statistics for categorical variables. The associations of type of KRT (kidney transplantation vs. hemodialysis) with the primary and secondary outcomes were examined in the total population and by reason for COVID-19 testing. Hazard ratios (HRs) and 95% confidence intervals (CIs) were estimated using Cox proportional-hazards regression models. To account for the competing risk of mortality, cause-specific hazards were calculated for hospitalization and ICU admission. Multiple models were constructed to account for potential confounders in a stepwise manner. Model 1 is a crude (unadjusted) model. In Model 2, we adjusted for age (continuous) and sex (male/female) and in model 3 we additionally adjusted for clinical frailty score. In model 4, we additionally adjusted for factors known to be associated with COVID-19 outcome, i.e. smoking (never, current, former), obesity (yes/no), hypertension (yes/no), diabetes (yes/no), heart failure (yes/no) and chronic lung disease (yes/no). In the final model (model 5), we further adjusted for time since the start of any KRT (continuous) and kidney function. The proportional-hazards assumption was investigated by testing interaction of log(time) with individual covariates. All multivariable models were based on datasets constructed using multiple imputation to account for missing data. For 210 patients (13%) information was missing on clinical frailty score, for 235 on obesity (14%), for 249 (15%) on serum creatinine (required to calculate eGFR) and for 73 patients (4%) on duration of kidney failure. The proportion of missingness for clinical frailty score (13.1% vs. 11.3%, p=0.30) and obesity (13.0% vs. 16.5%, p=0.06) was similar for hemodialysis patients and kidney transplant recipients, while serum creatinine was missing more often in hemodialysis patients (16.5% vs. 11.1%, p=0.004) and duration of kidney disease was missing more often in transplant recipients (2.5% vs. 8.9%, p<0.001). To account for missing information, multiple imputation was performed with the chained equations method using all variables included in Model 4. Fully conditional specification was employed, meaning that data from available cases was used and that each variable with missing values was imputed using a regression model conditional on all of the other variables specified in the imputation model. 13, 14 In total, 10 imputed datasets were created with 100 interactions. For the pooled coefficient and standard error Rubin´s Rules was used. 15 To examine the robustness of our findings, we performed several sensitivity analyses, which are described in the supplementary material. All analyses were performed using Stata version 14.0 (College Station, TX). A 2-sided -value less than 0.05 indicated statistical significance. Nephrology Dialysis Transplantation 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 RESULTS A total of 2,575 KRT patients who were diagnosed with COVID-19 between February 1 st and December 1 st , 2020 were included. After excluding patients on peritoneal dialysis due to their low number (n=99) and patients with missing information on the type of KRT (n=83), day 28 vital status (115 kidney transplant recipients and 221 dialysis patients) and/or the reason for COVID-19 screening (156 kidney transplant recipients and 433 dialysis patients), there were 1,670 patients left for the analyses. Of them, 496 were kidney transplant recipients and 1,174 hemodialysis patients ( Figure S1 ). The mean age of kidney transplant recipients was 56 years, which was 10 years younger than those on hemodialysis (Table 1) . Overall, 62% were male and 85% were white/Caucasian, which was not different for the two groups. The prevalence of diabetes mellitus, coronary artery disease, heart failure, chronic lung disease and current or former smoking was higher in hemodialysis patients, who also had a higher clinical frailty score. Eighty-five percent of the kidney transplant recipients were diagnosed with COVID-19 after being tested because of symptoms, whereas this was the case in 61% of the hemodialysis patients. Hemodialysis patients were more frequently diagnosed with COVID-19 as a result of a routine screening or because of a COVID-19 contact while being asymptomatic. Consequently, more kidney transplant recipients than hemodialysis patients presented with symptoms like cough, shortness of breath, headache, nausea or vomiting, diarrhea, myalgia or arthralgia, and fever. Although their O 2 saturation at presentation was similar to those of hemodialysis patients, kidney transplant recipients had a higher temperature, respiration rate, pulse rate and C-reactive protein (CRP) levels. Kidney transplant recipients more often used RAAS inhibitors than hemodialysis patients and all of them were on immunosuppression (Table 1) . Among patients tested because of symptoms, transplant recipients generally had a higher prevalence of COVID-19-related symptoms compared with hemodialysis patients ( Table 2 ). In comparison with those identified by routine screening, hemodialysis patients with COVID-19 identified by testing because of symptoms were older and had more comorbidities, whereas symptomatic kidney transplant recipients had similar comorbidities. In both patient groups those with symptoms had higher CRP levels (Table S1) . 28-day probability of death in kidney transplant recipients was 16.9% (95% CI: 13.9-20.5%), which was lower than the 23.9% (95% CI: 21.6-26.5%) mortality in the hemodialysis patients. Figure S2 shows the survival for the overall group and for the subgroup of patients identified by screening because of symptoms. (Table S2) . (Table S5) . Only ~6% of the deaths (n=23) were reported not to be caused by COVID-19. An analysis restricted to COVID-19 related deaths showed results similar to the main results. After excluding hemodialysis patients using immunosuppressive agents and/or who previously received a kidney transplant, the aHR for the association of being a kidney transplant recipient (vs. 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 12 interactions in the risk associated with kidney transplantation compared to being on hemodialysis were found between subgroups except for subgroups defined by age (<65/≥65 years) (p=0.02) (Table S13) . Transplantation 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 13 Since the start of the COVID-19 outbreak, it has been a topic of discussion in the nephrology community whether hemodialysis or kidney transplant patients are more affected by COVID-19 related mortality. Here we present analyses derived from ERACODA, the largest database with comprehensive individual level data of patients on dialysis or living with a kidney transplant infected by SARS-CoV-2 in Europe. Our data indicate that 28-day mortality is higher for kidney transplant recipients compared to hemodialysis patients after adequate adjustment for age, sex, frailty and comorbidities. Stratified analyses limiting the dataset to patients tested because of symptoms, confirmed that kidney transplant recipients have a higher mortality risk. Finally, we show that only very few hemodialysis patients were admitted to the ICU, less than patients with a kidney transplant. COVID-19 is particularly life threatening in patients on KRT, suggesting that kidney failure creates an environment for a more severe course of disease. 3 In our study, the unadjusted COVID-19 related 28-day mortality rate was 16.9% in transplant recipients and 23.9% in hemodialysis patients. These findings are in line with data from other regional and national registries. 6, 9, [16] [17] [18] These studies also show lower, or a trend towards lower, mortality in kidney transplant patients in a crude analysis compared to hemodialysis patients. This finding is not unexpected because in our study hemodialysis patients were on average ten years older and had more comorbidities. In a region-wide registry study from the Flanders region of Belgium, cumulative mortality was 29.6% versus 14.0% among patients on hemodialysis and kidney transplant recipients, respectively. Adjustment for age alleviated cumulative mortality for dialysis patients (19.9%) and conversely higher mortality for transplant patients (23%). 19 This study demonstrates that adjustment for age is the first step towards obtaining a more reliable comparison of the mortality burden in patients on various modalities of kidney function replacement. In addition, it should be accounted for burden differences in comorbidities. Diabetes, obesity, respiratory and cardiovascular disease are all well identified predictors of COVID-19 related death in the general population 2,5 as well as in kidney failure patients 8, 16, 18 , albeit to a lesser extent in these latter patient groups. 20 In a recent study, these were small studies. In the present study, the main finding was robust in the various sensitivity analyses that we performed. Analysis of overall instead of day 28 mortality showed similar results, as did exclusion of the very few dialysis patients using immunosuppressive treatments and/or had a kidney transplant previously. To account for potential selection bias, we provide an analysis of symptomatic and asymptomatic (contact or routine testing) patients separately; however, due to their small number, we were not confident that we could draw statistically well-founded conclusions for the latter. We observed that the risk of death associated with being a transplant recipient was considerably higher in patients over 65 years. This may reflect longer kidney disease duration and longer chronic exposure to immunosuppressive agents. However, adjustment for duration of kidney failure did not materially affect our results. It may therefore well be that elderly subjects are more vulnerable to the risk enhancing effect of immunosuppressive agents, just as in the general population. Under non-COVID-19 circumstances, kidney transplant recipients exhibit lower mortality rates than waitlisted dialysis patients after adjustment for age, sex, race, and cause of renal disease. 23 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 65%) than kidney transplant recipients 8 . The French nationwide registry noticed similar findings. 24 The risk of contracting SARS-CoV-2 infection is higher in hemodialysis patients consistent with the difficulties to achieve social distancing while travelling to and from dialysis units. It should therefore be noted that overall risk of mortality could be the same or lower in kidney transplant recipients in case the risk of getting infected is lower in these patients. Previous studies have also reported that though the incidence of COVID-19 was higher in waitlisted dialysis patients as compared to kidney transplant recipients, the mortality rate remained lower. 24-26 This can be accounted for by the fact that many COVID-19 cases in dialysis patients are detected by a general screening policy, even in asymptomatic patients. In the present study, adequate adjusted analysis documents that kidney transplant recipients exhibit a higher mortality rate compared to waitlisted patients. KRT patients have a frail immunological system. Chronic exposure to uremia alters the immune response in dialysis and kidney transplant recipients. In addition, a kidney transplant recipient requires lifelong immunosuppression, which affects both innate and adaptive immunity. Therefore, in kidney transplant recipients, viral infections are frequent 27 and lead to higher morbidity and mortality when compared to dialysis patients. 28 A role for immunosuppressive agents as the cause for the higher risk for COVID-19 mortality in kidney transplant recipients may be suspected. Indeed, when further examined in our data, patients during the first post-transplant year, i.e. when they are given the strongest immunosuppression, experience dramatically increased COVID-19 related mortality in comparison to waitlisted patients, a finding consistent with other studies 7, 29 . We also investigated the association of intensity and type of immunosuppressant use with mortality in kidney transplant recipients. Patients on dual therapy (vs. triple therapy) and immunosuppression excluding corticosteroids (vs. immunosuppression including corticosteroids) tended to have a lower risk of mortality, but these associations were not statistically significant (Table S14 and Table S15 , respectively). Therefore, we are not able to confirm the role of immunosuppressant use in the observed excess risk of mortality in kidney 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 might not include all patients in all participating centers. Testing policies may vary between centers and over time, but in general lead to reporting less cases in asymptomatic patients. Despite rapid implementation of telemedicine or scheduled calls in most centers during the pandemic, under-reporting of cases is still possible, particularly for transplant recipients. For these reasons, we also present the results of sensitivity analyses limited to the subset of transplant and hemodialysis patients that were identified in a similar manner (testing because of symptoms or hospitalization). We additionally accounted for any potential center effect. These analyses confirm our main findings. Second, ERACODA does not gather information on in-hospital patient management beyond 48 hours after admission. Change over time in recommendations for supportive care, immunosuppressive treatment and availability of specific therapies may have impacted outcome. Also, analysis taking into account a potential center effect did not show discordant results. Differences in in-hospital patient management between groups are therefore not likely to have had a major impact on our comparative results. In conclusion, this large European study demonstrates that kidney transplantation dramatically impacts mortality in kidney failure patients with COVID-19. Thus, kidney transplant recipients with COVID-19 should be closely monitored and need intensification of infection mitigation strategies and prioritization of effective and safe COVID-19-vaccine distribution. In addition, these findings suggest that postponing transplantations may be justified, especially during highly active phase of the pandemic. Investigation of the potential effect of immunosuppression on outcome is also urgently needed. Finally, our data indicate that intensive care management should be considered for kidney failure patients based on demographics, comorbidities and disease characteristics, and that the mere fact of being a hemodialysis patient should not discourage physicians to admit such patients to an ICU. All authors contributed to data collection, study design, data analysis, interpretation, and drafting of this paper. We thank all people that entered information in the ERACODA database for their participation, and especially all healthcare workers that have taken care of the included COVID-19 patients. Unrestricted research grants were obtained from the European Renal Association (ERA-EDTA), the Dutch Kidney Foundation, Baxter and Sandoz. Neither organization had any role in the design of the study, interpretation of results nor in writing of the manuscript. 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 20 SUPPLEMENTAL MATERIAL -TABLE OF CONTENTS Table S1 : Baseline characteristics of study population by type of kidney replacement therapy and reason for COVID-19 screening Table S2 : Association of kidney transplantation (KT) (vs. hemodialysis (HD)) with incidence of 28day mortality, overall and by reason for COVID-19 screening without multiple imputation (presented as hazard ratios (HR) with 95 % confidence intervals (CI)) 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 21 Table S10 : Association of kidney transplantation (vs. hemodialysis) with incidence of 28-day mortality, overall and by reason for COVID-19 screening (among hospitalized patients only) (presented as hazard ratios (HR) with 95 % confidence intervals (CI)) Transplantation 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 Transplantation 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 diseases: Results from an international registry. Gastroenterol 159: 481-491.e3, 2020. doi: 10.1053/j.gastro.2020.05.032 Page 24 of 37 Nephrology Dialysis Transplantation 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 Transplantation 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 Transplantation 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 Transplantation 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 Transplantation 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 Page 37 of 37 Nephrology Dialysis Transplantation 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study Factors associated with COVID-19-related death using OpenSAFELY CKD is a key risk factor for COVID-19 mortality COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention Results from the ERA-EDTA Registry indicate a high mortality due to COVID-19 in dialysis patients and kidney transplant recipients across Europe COVID-19-related mortality in kidney transplant and dialysis patients: results of the ERACODA collaboration COVID-19 outcomes in patients waitlisted for kidney transplantation and kidney transplant recipients Report of the COVID-19 Registry of the Spanish Society of Nephrology (SEN) ERACODA: the European database collecting clinical information of patients on kidney replacement therapy with COVID-19 The REDCap consortium: Building an international community of software partners A global clinical measure of fitness and frailty in elderly people Multiple Imputation by Fully Conditional Specification for Dealing with Missing Data in a Large Epidemiologic Study Multiple Imputation for Missing Data: Fully Conditional Specification Versus Multivariate Normal Imputation Statistical analysis with missing data Low incidence of SARS-CoV-2, risk factors of mortality and the course of illness in the French national cohort of dialysis patients COVID-19 and kidney transplantation: Results from the TANGO International Transplant Consortium